Der erste Krebsimpfstoff
Das Gute ist die erste Immunkrebstherapie, Provenge von Dendreon gegen Prostatakrebs die von bad money und drecks shorties versucht wurde zu töten und sie töteten mit der FDA tausende Männer die schon seit 2007 Provenge hätte erhalten sollen! Pfui daifi, drecks Korruption und Chemokartelle!
Die alten Kurse werden wir 2012 hinter uns lassen! ;)
Optionen
| Boardmail an "crivit" |
Wertpapier: Dendreon |
http://keyinvest-ch.ubs.com/seite?pageID=25&newsID=263410
Optionen
| Boardmail an "crivit" |
Wertpapier: Dendreon |
Gründe: EU/ROW Partner , steigende Umsätze, weltweit alleinige Rechte und eine einmalige
Plattform um andere Krebsarten wie Brust, Blutkrebs.... zu behandeln und das
Alles ohne Chemo sondern mit dem eigenem Immunsystem!
Go Debie go......................................................
hat so eben auch so ein mittel gegen krebs, und der kurs hat auch
schon reagiert.
bin derzeit weder dort, noch hier investiert
http://www.ariva.de/generex_biotechnology-aktie
http://video.cnbc.com/gallery/?video=3000066264
By: iStockAnalyst | Jan 06, 2012 | Stocks: DNDN,
inShare0
Deutsche Bank (DB : 36.31, -0.69) maintained its "Buy" rating and price target of $20 on biotechnology company Dendreon Corp. (NASDAQ:DNDN : 14.02, 0.23).
The company preannounced Q4:11 Provenge net sales of $77 million, which was well ahead of guidance of limited growth vs. Q3, DB said. Provenge is the company's prostate cancer therapy.
"We view this as a positive & the clarity investors on the sidelines have been waiting for as it indicates that Provenge is gaining traction w/ urologists," DB said. "We are increasing our Provenge ramp but maintaining peak sales."
The stock, which has been trading in the 52-week range between $6.46 and $43.96, rose 12.9 percent to $12.00.
On 1/3/2012 (but news went out on 1/4/2012 after markets closed), Dendreon (NASDAQ: DNDN) granted a grand total of 1,387,000 shares to executives and directors. Quite a big number both in dollar terms ($10,000,000 give or take) and as a percentage of company capital: It’s somewhat less than 1% of total float.
All stock has been granted for free. Exercise price is $0.
Breakdown of stock grants is as follows:
This restricted stock award vest as follows: 25% on the first year anniversary and 6.25% quarterly thereafter:
John E. Osborn, EVP, General Counsel: 150,000
Gregory T. Schiffman, CFO, EVP of Finance & Treasure: 150,000
Mark W. Frohlich, EVP, Clinical Affairs & Chief Medical Officer, 150,000
Greg Cox, VP, Finance, 52,000
Richard J. Ranieri, EVP, Human Resources, 200,000.
All restricted stock shares vest (become sellable) on date of grant:
Richard B. Brewer, Director, 25,000
Susan Bayh, Director, 25,000
Pedro Granadillo, Director, 25,000
David C.Stump, Director, 25,000
John H. Johnson, Director, 25,000
Bogdan Dziurzynski, Director, 25,000
Gerardo Canet, Director, 25,000
Douglas G. Watson, Director, 25,000.
The award will vest ratably over 3 years based upon the achievement of Company performance goals:
Mitchell H. Gold, President & Chief Executive Officer, 460,000.
All restricted stock shares are fully vested (become sellable) on the first anniversary of the date of transaction:
Dennis M. Fenton, Director, 25,000
As if to mitigate shareholders’ anger, the following day Dendreon announced fourth quarter revenues and updated on commercialization. News was good and the stock price reacted accordingly. They almost doubled since.
I have two themes to develop today.
One is: why did management grant itself a so large amount of common shares?
The other is: how much is Dendreon worth?
Well, just start with a tentative answer of the second question.
I prepared a comparison table, as a valuation exercise.
We see that large, stable biotechnology companies have Price to Sales ratios ranging from 3.84 to 6.96; and Price to Earnings ratios from 16.86 to 30.79.
Company
P/S
P/E
Dendreon Valuation Table
Amgen Inc. (AMGN)
3.84
16.86
Gilead Sciences, Inc. (GILD)
4.12
13.32
Celgene Corporation (CELG)
6.96
30.79
Biogen Idec Inc (BIIB)
5.72
24.34
I also want to add some spice here.
On Saturday, January 7, 2012, Bristol-Myers Squibb Company (NYSE:BMY – News) and Inhibitex, Inc. (Nasdaq:INHX – News) announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction values Inhibitex approximately $2.5 billion.
Inhibitex, Inc. is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. It does not have any single product on the market to date.
So, back to our question: How much is Dendreon worth?
Dendreon said:
■At the end of the fourth quarter, completed in-servicing for more than 840 total sites, of which: ■More than 590 sites have infused PROVENGE, which represents the greatest growth in infusing sites quarter over quarter; and
■Approximately 615 sites have either infused the product or have their patients scheduled for their first PROVENGE regimen.
■Improved PROVENGE reimbursement landscape for customers and patients: ■Reported average time to payment is less than 30 days for physicians, which is better than industry standard, reflecting an improved reimbursement landscape due to a national coverage decision and activation of a Q-code that accelerates electronic adjudication of claims.
Dendreon also said:
■EU application filed. Discussing partnering.
■“compelling” data to be presented at AUA and ASCO on both effect of Provenge at tissue level pre-surgery AND further analysis of Frovenge effect and “true” clinical benefit of Provenge.
■EU application filed. Discussing partnering.
■Sequencing study for Provenge and Zytiga.
■Discussing Japan with regulatory authorities.
■Projects underway to reduce COGS with automation.
■Special sales team for urology practices and with key aim of making large urology practices big prescribers.
I think we have enough data in place to try some “what if”.
What if Dendreon reaches $500 M within twelve months for now?
Valuation would range from $2B to $3.5B if it were a mature biotechnology. But, since DNDN is in “growth mode”, it think it might get an even higher price.
It all means a price per share (pps) in the $14-$28 range.
What if we add the $2.5B “acquisition premium” Bristol-Myers Squibb Company paid to gain control of Inhibitex? Then pps would be in the $30-$42.
Now, you see, I think I can give an answer to the first question: Why did management grant itself a so large amount of common shares?
In my opinion, management knows that current DNDN stock price is low and that a high enough offer (say, in the mid $30s) would be impossible to resist and would also still be a bargain for the acquirer.
I want to close this article with another “What If”, to see if, say, a hostile offer of $40 per share would be a bargain for the acquirer.
What if, in 2015, Dendreon reaches $1.5B in sales in the USA, $1B in Europe and $0.5B in Japan?
Dendreon would then have $3B in sales and we know from management that Dendreon would enjoy a 50% earnings margin. That would mean earnings of $1.5B. A reasonable Price-to-Earnings ratio might be 20. Just multiply $1.5B x 20 and we get $30B.
It would mean a pps of $210.
buyout rumors:
Amgen to Acquire Dendreon
http://www.benzinga.com/trading-ideas/long-ideas/...nzinga+News+Feed)
Optionen
| Boardmail an "crivit" |
Wertpapier: Dendreon |
They will be replaced by John Johnson, known to biotech investors for taking control of ImClone Systems in 2007 and eventually selling the company to Eli Lilly for $6.5 billion. Johnson was already on the company’s board.
Johnson will take the CEO role immediately. Gold will serve as executive chairman until June 30, at which point Johnson will take that role, too. Brewer, the chairman, will remain a director.
(zitiert aus Forbes vom 1. Feber 2012, M. Herper)
Optionen
| Boardmail an "Parocorp" |
Wertpapier: Dendreon |
FREE Breaking News Alerts from StreetInsider.com!
E-mail Address
More News related to AMGN
Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval
Wedbush Starts NPS Pharmaceuticals Inc. (NPSP) at Outperform; GATTEX Up for Approval, NATPARA Next
Notable 52-Week Highs and Lows of the Day 02/06: (THLD) (GILD) (AAPL) High; (CYDE) Low
Dendreon (DNDN) Now a Double on the Year Amid M&A Speculation
Lazard Capital Downgrades Amgen (AMGN) to Sell
More News related to AMGN
More News related to DNDN
Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval
Stock with implied volatility movement; DNDN
Notable 52-Week Highs and Lows of the Day 02/06: (THLD) (GILD) (AAPL) High; (CYDE) Low
Dendreon (DNDN) Now a Double on the Year Amid M&A Speculation
Notable Analyst Rating Changes 02/03: (DNDN) (BBT) (NOV) Upgraded; (RIMM) (VRTX) (AET) Downgraded
More News related to DNDN
More News related to Analyst Comments
Canaccord Genuity on Life Sciences/Biomedical Devices and Services: Take on Q4 and Beyond
Goldman Sachs Raises Estimates On Wynn Resorts (WYNN), Maintains Neutral Rating
Canaccord Genuity Maintains a 'Hold' on Genomic Health (GHDX); Slightly Misses in Q4; Forms New Genetics Subsidiary
Canaccord Genuity Reiterates a 'Buy' on Orthofix (OFIX); Clearing Up Legal Overhangs
Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval
More News related to Analyst Comments
February 7, 2012 8:28 AM EST
Canaccord Genuity maintains a 'Buy' on Dendreon (NASDAQ: DNDN) price target raiesd from $16 to $18.
Analyst, George Farmer, said, "We maintain our rating and raise our target as a negative FDA stance on Amgen’s (Nasdaq: AMGN) XGEVA de-risks the outlook for DNDN’s prostate cancer vaccine, Provenge."
"Encouraging December sales in the face of holiday conflicts had justified our previously bumped-up 2012 $426M sales estimate. Our new 2012 $458M estimate assumes near-term acceleration of “same-store-sales” fueled by higher physician perception, although we caution that negative practitioner impressions of logistics and cost still lingers. Nevertheless, $500M in sales this year – a management-declared cash flow break-even point – is not far fetched, in our view."
For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.
Shares of Dendreon closed at $16.53 yesterday, with a 52 week range of $6.46-$43.96.
MMhh, Freitag die 18$, dat wäre es doch! ;)
O.o
GLTA
Optionen
| Boardmail an "crivit" |
Wertpapier: Dendreon |
Dendreon wird "the standard of care" in der Prostatakrebsbehandlung werden da neueste Studien zeigen daß Provenge auch bei beginnenden Prostatakrebs sehr gut wirkt!
50 US Dollar Kursziel innerhalb eines Jahres bzw. Übernahme durch big pharma!
bekommen die aktionäre am ende nicht ein mittelwert des kurses der letzten 6 monate
( ist doch wenig )
ist richtig, sofort zu verkaufen, wenn übernahme gerüchte da sind
und nicht lange warten?
danke für info.
..
Dendreon Announces New Time for Fourth Quarter and Year-End Financial Results Conference Call and Webcast Presentations at Upcoming Conferences
Call to be held on Monday, February 27, 2012, at 9:00 a.m. ET
Press Release: Dendreon Corporation – 11 hours ago.. .
.
1
... .
.
Companies:.
.
.Dendreon Corp.
.
.
.
RELATED QUOTES.
.
Symbol
Price
Change
DNDN
13.73
0.00
.
.
..
.
.
SEATTLE--(BUSINESS WIRE)--
February 22, 2012 – Dendreon Corporation (Nasdaq: DNDN - News) today announced that management will host a conference call on Monday, February 27, 2012, at 9:00 a.m. ET to review fourth quarter and year-end financial results. This conference call was previously scheduled at 4:30 p.m. ET on the same date.
Access to the discussion may be obtained as follows:
Time:
9:00 a.m. ET / 6:00 a.m. PT
Date:
February 27, 2012
Dial-in:
1-877-548-9590 (domestic) or +1-720-545-0037 (international);
conference pass code: 46511476
Webcast:
www.dendreon.com (homepage and investor relations section)
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-585-8367 or +1-404-537-3406 for international callers; the conference ID number is 46511476. The replay will be available from 12:00 p.m. ET on Monday, February 27, until 11:59 p.m. ET on Monday, March 5. In addition, the webcast will be archived for on-demand listening for 90 days at www.dendreon.com.
In addition, Dendreon Corporation also announced that management will present at the following conferences:
• RBC Capital Markets’ Healthcare Conference in New York City, on February 28, 2012, at 3:35 p.m. ET
• Citi 2012 Global Healthcare Conference in New York City, on February 29, 2012, at 2:00 p.m. ET
The presentations will be audio webcast live and available for replay from Dendreon’s website, www.dendreon.com. If you are unable to listen to the live webcasts, they will be archived on the site following the presentation. To access the replays, go to the Investor Relations section of the website.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
.
.
Contact:.
.
Dendreon Corporation
Katherine Stueland, 206-829-1522
Vice President, Corporate Communications and Investor Relations
kstueland@dendreon.com....
.
.
@yahoofinance on Twitter, become a fan on Facebook